Ostermann Marlies, Philips Barbara J, Forni Lui G
Crit Care. 2012 Sep 21;16(5):233. doi: 10.1186/cc11380.
The recognition that acute kidney injury (AKI) is a significant independent risk factor for morbidity and mortality has resulted in a substantial number of publications over the past 5 years or more. In no small part these have, to a degree, highlighted the inadequacy of conventional markers of renal insufficiency in the acute setting. Much effort has been invested in the identification of early, specific AKI markers in order to aid early diagnosis of AKI and hopefully improve outcome. The search for a 'biomarker' of AKI has seen early promise replaced by a degree of pessimism due to the lack of a clear candidate molecule and variability of results. We outline the major studies described to date as well as discuss potential reasons for the discrepancies observed and suggest that evolution of the field may result in success with ultimately an improvement in patient outcomes.
认识到急性肾损伤（AKI）是发病率和死亡率的一个重要独立危险因素，在过去5年或更长时间里催生了大量的出版物。在很大程度上，这些出版物在一定程度上凸显了急性情况下传统肾功能不全标志物的不足。为了辅助AKI的早期诊断并有望改善预后，人们投入了大量精力来寻找早期、特异性的AKI标志物。由于缺乏明确的候选分子和结果的变异性，对AKI“生物标志物”的探索已从早期的希望转变为一定程度的悲观。我们概述了迄今为止所描述的主要研究，讨论了观察到差异的潜在原因，并表明该领域的发展可能会取得成功，最终改善患者的预后。
